Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Adaptive Biotechnologies Q3 Adj. EPS $(0.15), Inline, Sales $60.200M Miss $64.643M Estimate

Author: Benzinga Newsdesk | November 05, 2025 07:40pm
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 31.82 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $60.200 million which missed the analyst consensus estimate of $64.643 million by 6.87 percent. This is a 29.64 percent increase over sales of $46.435 million the same period last year.

Posted In: ADPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist